Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Lower Doses of Plerixafor Use Is Sufficient to Effectively Mobilize PBSC (Peripheral Blood Hematopoetic Stem Cells) When Compared to Standard Administration

Hakan Goker, MD, Eylem Eliacik, MD, Fevzi Altuntas, MD, Emre Tekgunduz, MD, Evren Ozdemir, MD, Ayse Isik, MD, Omur Kayikci, MD, Ali Hakan Kaya, MD, Salih Aksu, MD, Ibrahim C. Haznedaroglu, MD, Nilgun Sayinalp, MD, Haluk Demiroglu, Osman Ilhami Ozcebe, MD, Yahya Buyukasik, MD

Blood (2014) 124 (21): 5830.

https://doi.org/10.1182/blood.V124.21.5830.5830

Published: 2014

Journal Articles

Prognostic Factors for Survival of Elderly Patients with Acute Myeloid Leukemia after Intensive Chemotherapy: Validation of 3 Popular Prognostic Models

Ebru Koca, MD, Aysun Halacoglu, MD, Umit Yavuz Malkan, MD, Deniz Arica, MD, Sema Karakus, MD, Hakan Goker, MD, Ibrahim C. Haznedaroglu, MD, Nilgun Sayinalp, MD, Yahya Buyukasik, MD

Blood (2014) 124 (21): 5332.

https://doi.org/10.1182/blood.V124.21.5332.5332

Published: 2014

Journal Articles

Experience With BFM 95 Pediatric Regimen In Adult ACUTE Lymphoblastic Leukemia

Hakan Goker, MD, Eylem Eliacik, MD, Ayse Isik, MD., Ibrahim C. Haznedaroglu, MD, Prof, Nilgun Sayinalp, MD, Salih Aksu, MD, Osman Ozcebe, MD, Yahya Buyukasik, MD.

Blood (2013) 122 (21): 5015.

https://doi.org/10.1182/blood.V122.21.5015.5015

Published: 2013

Journal Articles

Use Of Nilotinib As a First Line Treatment In Adult Patients With Philadelphia Chromosome-Positive and Chronic Phase Myeloid Leukemia

Guray Saydam, MD, Prof, Ibrahim C. Haznedaroglu, MD, Prof, Leylagul Kaynar, MD, Prof, Akif S. Yavuz, MD, Prof, Ridvan Ali, MD, Prof, Birol Guvenc, MD, Prof, Olga M. Akay, MD, Zafer Baslar, Professor Doctor, Ugur Ozbek, MD, Prof, Mehmet Sonmez, M.D., Demet Aydin, MD, Mustafa Pehlivan, MD, Assoc Prof, Bulent Undar, MD, Prof, Simten Dagdas, MD, Assoc Prof, Orhan M. Ayyildiz, MD, Prof, Diyar Z. Akkaynak, MD, Ilkiz M. Dag, MD, Osman Ilhan, MD, Prof

Blood (2013) 122 (21): 2742.

https://doi.org/10.1182/blood.V122.21.2742.2742

Published: 2013

Journal Articles

Functional Proteomics of Ankaferd Blood Stopper

Nejat Akar, Duygu Ozel Demiralp, Ibrahim C. Haznedaroglu, Hakan Goker

Blood (2008) 112 (11): 4103.

https://doi.org/10.1182/blood.V112.11.4103.4103

Published: 2008

Journal Articles

Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line

Blood (2008) 112 (11): 185.

https://doi.org/10.1182/blood.V112.11.185.185

Published: 2008

Journal Articles

Haemostatic Actions of the Folkloric Medicinal Plant Extract, Ankaferd Blood Stopper.

Hakan Goker, MD, Ibrahim C. Haznedaroglu, MD, Sevil Ercetin, Ph.D, Serafettin Kirazli, Umit Akman, Yusuf Ozturk, Cahit H. Firat

Blood (2007) 110 (11): 3943.

https://doi.org/10.1182/blood.V110.11.3943.3943

Published: 2007

NARROW

Lower Doses of Plerixafor Use Is Sufficient to Effectively Mobilize PBSC (Peripheral Blood Hematopoetic Stem Cells) When Compared to Standard Administration

Prognostic Factors for Survival of Elderly Patients with Acute Myeloid Leukemia after Intensive Chemotherapy: Validation of 3 Popular Prognostic Models

Experience With BFM 95 Pediatric Regimen In Adult ACUTE Lymphoblastic Leukemia

Use Of Nilotinib As a First Line Treatment In Adult Patients With Philadelphia Chromosome-Positive and Chronic Phase Myeloid Leukemia

Functional Proteomics of Ankaferd Blood Stopper

Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line

Haemostatic Actions of the Folkloric Medicinal Plant Extract, Ankaferd Blood Stopper.

Email alerts

ASH Publications

American Society of Hematology

Lower Doses of Plerixafor Use Is Sufficient to Effectively Mobilize PBSC (Peripheral Blood Hematopoetic Stem Cells) When Compared to Standard Administration

Prognostic Factors for Survival of Elderly Patients with Acute Myeloid Leukemia after Intensive Chemotherapy: Validation of 3 Popular Prognostic Models

Experience With BFM 95 Pediatric Regimen In Adult ACUTE Lymphoblastic Leukemia

Use Of Nilotinib As a First Line Treatment In Adult Patients With Philadelphia Chromosome-Positive and Chronic Phase Myeloid Leukemia

Functional Proteomics of Ankaferd Blood Stopper

Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line

Haemostatic Actions of the Folkloric Medicinal Plant Extract, Ankaferd Blood Stopper.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only